ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Updates

SUB-TYPE:

AmerisourceBergen becomes Cencora, in alignment with the company’s growing global footprint and central role in pharmaceutical access and care

 

New name of company reflects unified global presence and collective goal of creating healthier futures by accelerating positive outcomes for customers and their patients

 

Company announces more than $5 million commitment to global corporate philanthropic efforts

 

 

CONSHOHOCKEN, Pa. (August 30, 2023) – Cencora, Inc. (NYSE: COR) today announced the completion of its name and stock ticker change from AmerisourceBergen Corporation (NYSE: ABC), marking the latest stage of the company’s evolution as a leader in global pharmaceutical services. Cencora will begin trading under the new ticker symbol “COR” on the New York Stock Exchange at the open of the market trading today, August 30, 2023. 

 

Under the new name Cencora, the company unifies its 46,000 employees – across several global business segments – under one identity, propelled by a bold vision and purpose-driven approach to creating healthier futures.

 

The new name underscores Cencora’s experience and vision when it comes to connecting manufacturers, providers, pharmacies and patients, and ensuring the consistent, reliable flow of treatments to those who need them at a time of growing complexity.

 

"Today is a significant and exciting milestone for Cencora. Our new name is a reminder of our customers, their patients, and our team members who are at the center of everything we do,” said Steven H. Collis, Chairman, President & Chief Executive Officer of Cencora. “It represents the healthier futures we strive for serving as a trusted industry partner that prioritizes innovation, advocates for patient access, and advances strategic partnerships across the global pharmaceutical value chain.”

 

As a global healthcare company, Cencora will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access across the globe.

 

Aligned with the company’s purpose, and to commemorate this seminal moment in the organization’s history, Cencora also announced a $5 million donation to the Cencora Impact Foundation, formerly known as the AmerisourceBergen Foundation, an independent not-for-profit charitable giving organization. The donation will be used to launch the Cencora Healthier Futures Grant Program, which aims to identify opportunities to support those on the front lines of healthcare in underserved populations who are driving innovation in global health. Targeted donations from the Cencora Healthier Futures Grant Program, operated by Cencora Impact Foundation, will go toward nonprofits and charities around the world that are advancing access to care and directly impacting communities in need.

 

The inaugural donation out of the Cencora Healthier Futures Grant Program will be a $500,000 grant made to the UNICEF Health Fund, which focuses on ensuring every child has the ability to survive and thrive by providing strong primary healthcare systems, training healthcare professionals, and working closely with national governments to ensure programs are replicable at scale. These system-wide responses aim to reduce the number of maternal and newborn deaths, provide children with immunizations, reduce malnutrition, address adolescent mental health, and combat the rise of non-communicable diseases. 

 

“We are grateful for support from the Cencora Impact Foundation to help UNICEF deliver large-scale, sustainable results in ensuring the health of the world’s most vulnerable children,” said V. Renée Cutting, Chief Philanthropy Officer, UNICEF USA.

 

Cencora Ventures, formerly known as AB Health Ventures, the company’s dedicated corporate venture fund, has also committed to donating 10% of future realized profits to support the efforts of the Cencora Impact Foundation and its continued work to improve healthcare access globally.

 

For more information about the rebrand and updated design and branding elements, visit: www.cencora.com

 

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.cencora.com

 

cen

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Loceryl nail lacquer

Galderma (U.K.) Limited has informed the MHRA that a pallet of Loceryl 5% w/v Medicated Nail Lacquer from a batch licensed only for distribution in Ireland has been inadvertently placed into the UK supply chain due to a warehousing error at their UK pre-wholesaler. Although Loceryl is a registered medicine in both Ireland and the UK, there are differences between these products in the product labelling and Patient Information Leaflet (PIL) packaged with the medicine.

 

 

MHRA drug alert date: 29th August 2023

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-galderma-uk-limited-loceryl-5-percent-w-slash-v-medicated-nail-lacquer-5-dot-0-ml-el-23-a-slash-31?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9a7e9437-f55e-4f24-82a6-d91ff2f6df4f&utm_content=immediately

 

Pip code

Product

Supplier

Affected Batches

0256313

LOCERYL NAIL LACQUER

 GALDERMA (U.K.)

2212421*

 

 

 

This is a caution in use only we are not accepting stock returns

 

Further Information

 

If you require more information, have further medical information enquiries (including replacement PIL enquiries) then please e-mail: medinfo.uk@galderma.com. For stock control queries, please contact: sales.uk@galderma.com

 

SUB-TYPE:

Supporting the NHS – a Q&A with couple who both work for the NHS

Last month we celebrated 75 years of the NHS. This prompted us to take look closer at our amazing National Health Service. We caught up with a Jim (a GP) and Marie (an intensive care nurse) who have both worked for the NHS for over thirty years.

 

 

What has your experience been working with the NHS?

 

Jim: I am very proud to have worked for the NHS for 36 years and it is a privilege to work for such an amazing organisation. The NHS has evolved and changed over the years to accommodate the changing demographics and needs of its population. It has been incredibly hard work but enormously rewarding.

 

Marie: I’ve worked for the NHS for 40 years and my experience has generally been very good. Whilst the work has been difficult both mentally and physically, particularly in the last few years, it is incredibly rewarding. Working alongside amazing colleagues helps you through the tougher moments.

 

Coming out of the pandemic, how has your work evolved?

 

Jim: We have embraced new technology, supported our patients and each other and tried to develop strategies to cope with a staggering increase in demand.

 

Marie: More of the day-to-day has moved online, it is much busier, there are less staff and higher expectations. It must be said that the pandemic has drastically changed the way that we work, and the way that the public see us. That said, I feel immensely proud to have been able to work in intensive care during the pandemic. It was extremely difficult, but the work that every member of staff did during that time was incredible.

 

Do you have a message for the NHS as it celebrates its 75th year?

 

Jim: Keep working hard to care for your patients, embrace change, support your colleagues and staff. Know that you are doing a great job and are much appreciated.

 

Marie: The NHS is a wonderful institution that I’ve been proud to work for my whole career. My message to all NHS workers is to keep doing what you’re doing – the hardest moments will be worth it; you are making a difference every day.

 

nhs

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall - Sodiofolin 50 mg/ml solution for injection/infusion

 

Medac GmbH (t/a medac Pharma LLP) is recalling the products and respective batches in this notification due to particles detected during long-term stability tests.

Further to EL(23)/A26 medac GmbH (t/a medac Pharma LLP) have identified further batches that are impacted. medac GmbH (t/a medac Pharma LLP) is recalling the products and respective batches in this notification due to particles detected during long-term stability tests. As stated in the Summary of Product Characteristics (SmPC): ‘Only clear solutions without visible particles should be used.’. These batches are being recalled as a precautionary measure and the root cause analysis investigation remains ongoing.

 

MHRA drug alert date: 21 August 2023

 

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50-mg-slash-ml-solution-for-injection-slash-infusion-100mg-slash-2ml-vial-el-23-a-slash-28?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=57648150-86b0-4190-81bc-49b6880f578d&utm_content=immediately


 

Pip code
Product description
Supplier
Batch Numbers
ALLIANCE HEALTHCARE DO NOT STOCK
Sodiofolin 50mg/ml solution for injection/infusion
Medac Pharma LLP
D210211C D210211D D210211F D210211G D210211H

 

Further Information

For all medical enquiries, please contact medical information at medac Pharma LLP by email to info@medacpharma.co.uk or by telephone 01786 458086.

 

 

SUB-TYPE:

Changes to Opening Hours - August 2023

 

To help keep our customers informed of changes to our service later this month, we have published the following changes to our opening hours from 25-29 August 2023:

 

England, Wales & NI August Bank Holiday Opening Hours 2023

Scotland Opening Hours 25-29 August 2023

 

SUB-TYPE: CLASS 2 RECALL

Class 2 recall-Various Braun products

B. Braun Medical Limited is recalling various product batches as a precautionary measure after traces of midazolam were detected in the batches listed in this notification.

 

MHRA Drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-b-braun-medical-ltd-various-products-el-23-a-slash-27?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=d9a6644a-a63e-49c8-a1c5-8eb3269f9399&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

8437352

FLUCONAZOLE INF 2MG/ML BRN

 BRAUN B MEDICAL LTD MOV

21473402  22125401

6802532

Paracetamol 10mg/ml Solution for Infusion

 BRAUN B MEDICAL LTD MOV

21357402 21357403 21423402 21424401

Alliance Healthcare do not stock

Gentamicin 3mg/ml solution for infusion 120ml

 BRAUN B MEDICAL LTD MOV

21025402 21056410

Alliance Healthcare do not stock

Gentamicin 3mg/ml solution for infusion 80 ml

 BRAUN B MEDICAL LTD MOV

21056409  21427416

Alliance Healthcare do not stock

Glucose Intravenous Infusion BP 5%

 BRAUN B MEDICAL LTD MOV

22041405

Alliance Healthcare do not stock

Ibuprofen 400mg Solution for Infusion

 BRAUN B MEDICAL LTD MOV

21095409

Alliance Healthcare do not stock

Ibuprofen 600mg Solution for Infusion

 BRAUN B MEDICAL LTD MOV

21096410

Alliance Healthcare do not stock

Ibuprofen 200mg Solution for Infusion

 BRAUN B MEDICAL LTD MOV

22133402

Alliance Healthcare do not stock

Sodium Chloride 0.9% w/v Intravenous Infusion BP

 BRAUN B MEDICAL LTD MOV

21261404 21384403 21433401 22123413 22165411 23104401

Alliance Healthcare do not stock

Water for Injections BP, solvent for parenteral use

 BRAUN B MEDICAL LTD MOV

21231404 21387412

 

Further Information

 

For stock control enquiries please contact via email or telephone: Josh Watts: Product Manager, email: josh.watts@bbraun.com or telephone: 07973 976257

 

For information about the recall please contact via email or telephone: Catherine Clulow: Local Vigilance and Project Coordinator, email: recalls.uk@bbraun.com or telephone: 0114 2259155

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

SUB-TYPE:

Supporting the NHS – a Q&A with Victoria Hoy, Pharmacy Procurement and IT Manager, Royal Surrey Foundation Trust

 

Earlier this month we celebrated 75 years of the NHS. This prompted us to take look closer at how we support our amazing National Health Service. We caught up with one of the pharmacists we work with on a daily basis and asked about her experiences of working with the NHS and the working relationship with Alliance Healthcare.

 

Do you enjoy working for the NHS?

The NHS have had a lot of ups and downs over the years, in particular the challenges we faced with Covid. Caring for our patients is obviously our main priority, so when we do face difficult times, we are like a family who support and help each other through, which is a wonderful thing to be a part of.

 

How would you describe working with Alliance Healthcare?

Alliance Healthcare are a huge part of our patient care, particularly in the pharmacy world. Knowing that we have a reliable source to provide of a huge range of medications means we can ensure there are no hold ups to care and can continue to look after our patients.  In my experience, the service you provide has always been extremely dependable so when we are rushed off our feet, we know the experience we receive from you will be stress free.

 

Coming out of the pandemic, how has your work evolved?

We had to become a lot more reactive as our patients and staff got used to us being able to source products quickly and efficiently during that time. This expectation has continued as we move out of the pandemic, so we have learned to adapt our work processes and order medications as soon as we are asked to.

 

How did you celebrate 75 years of the NHS?

Our Trust brought in ice cream vans and staff were all able to get free ice cream for the day. There were also various events going on within the Trust which allowed staff and patients to celebrate together.

 

Do you have a Birthday message for them?

Happy Birthday NHS, you have looked after so many people over the years, including many of my family and friends. You provide access to care for all, and I hope you continue to do so for many years to come. Through the bad times and good, I am proud to be an NHS employee.

 

nhs2

SUB-TYPE:

Alliance Healthcare Team Members Complete 6-hour Trek in Aid of Alzheimer’s Society Dressed as ‘Glamorous Grannies’

 

Alliance Healthcare UK team members Nick Atkins, Swansea Service Centre Manager, and Karl Goodall, Swansea Driver Team Manager, successfully climbed Pen y Fan in South Wales in aid of Alzheimer’s Society.

 

Pen y Fan, situated in the Brecon Beacons National Park, is the highest British peak south of the Cadair Idris in Snowdonia standing at 886 metres above sea level.

 

Nick and Karl embarked on the trek dressed as ‘glamorous grannies’ - donning wigs, tights, and dresses to climb the famous peak and raise money for those with dementia. Dementia is a disease which most commonly affects those aged 65 and over and 65% of the 944,000 people living with dementia in the UK are women*. The pair completed the mountain trek in six hours, carrying an Alliance Healthcare medicines cool box weighing over 35 kg. They have so far raised over £1,500 for Alzheimer’s Society, a cause close to Nick Atkins’s heart.

 

Alzheimer’s Society is a national care and research charity for people with dementia and their carers. The charity comprises trusted experts, campaigners, researchers, and clinicians who are attempting to tackle the biggest challenges facing people living with dementia. Alzheimer’s Society Cymru is the only UK dementia charity to fund both biomedical and care research.

 

Alzheimer’s Society Cymru, said:

“Alzheimer’s Society Cymru is delighted that Nick and Karl from Alliance Healthcare scaled Pen Y Fan as ‘glamourous grannies’ to raise funds and awareness, particularly when Nick is directly affected by dementia. With over 50,000 people living with dementia in Wales and 900,000 across the UK, there has never been more important time to support our work.

 

“Alzheimer’s Society Cymru relies on the generosity of its supporters, like Nick and Karl and Alliance Healthcare, to help us continue our vital work, providing help and hope for people affected by dementia. We cannot thank Nick and Karl enough for their amazing efforts to support Alzheimer’s Society Cymru.”

 

Nick Atkins, Swansea Service Centre Manager, said:

“We decided to dress up as glamorous elderly ladies to bring attention to the demographic that are most affected by the disease. Raising money for Alzheimer’s Society is very close to my heart as my mother is currently in the later stages of this horrible disease. It’s great that every penny raised through this event will go to such a worthy cause.”

 

Karl Goodall, Swansea Driver Team Manager, said:

“After doing many charity events previously I now needed a different challenge. When Nick and I spontaneously came up with this unique idea I knew it would be a sure way to raise money and awareness for such a great cause!”

 

You can still donate to their cause by visiting the following link: Fundraiser by Nicholas Atkins : The Betty & Edna Mountain Climb (gofundme.com)

 

If you need help, visit alzheimers.org.uk or call 0333 150 3456 to speak to one of Alzheimer’s Society Cymru’s expert dementia Advisers.

 

az1   az2

 

SUB-TYPE: CLASS 2 RECALL

Class 2 recall-Sodiofolin 50 mg/ml solution for injection/infusion

medac GmbH (t/a medac Pharma LLP) is recalling the products and respective batches in this notification due to particles detected during long-term stability tests.

 

MHRA drug alert date: 20th July 2023

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50-mg-slash-ml-solution-for-injection-slash-infusion-400mg-slash-8ml-vial-el-23-a-slash-26?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=f7cf9bf8-abed-479c-8071-de26a4cdf913&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE HEALTHCARE DO NOT STOCK

Sodiofolin 50 mg/ml solution for injection/infusion

medac Pharma LLP

G220393B G220393C

 

Further Information

For all medical enquiries, please contact medical information at medac Pharma LLP by email to info@medacpharma.co.uk or by telephone 01786 458086.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

SUB-TYPE:

National Patient Safety Alert: Shortage of GLP-1 receptor agonists

Message on behalf of DHSC and NHS as at 18 July 2023

 

The Department of Health Social Care (DHSC) and NHS have released a national patient safety alert in relation to a shortage of GLP-1 receptor agonists. 
 
The DHSC and NHS have said there are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Supplies are not expected to stabilise to meet full market demand until at least mid-2024. 
 
Please see listed below the GLP-1RAs affected:
 
Semaglutide injection and tablets: 
• Ozempic® 0.25 mg, 0.5mg and 1mg solution for injection in pre-filled pen 
• Rybelsus® 3mg, 7mg and 14mg tablets 
 
Dulaglutide: 
• Trulicity® 0.75 mg, 1.5mg, 3mg and 4.5mg solution for injection in pre-filled pens 
 
Liraglutide: 
• Victoza® 6mg/ml solution for injection in prefilled pen 
• Saxenda® 6mg/ml solution for injection in prefilled pen [licensed for weight management]
 
Exenatide: 
• Byetta® 5micrograms/0.02ml and 10micrograms/0.04ml solution for injection 1.2ml pre-filled pens 
• Bydureon® 2mg/0.85ml prolonged-release suspension for injection 1.2ml pre-filled pens
 
The off-label use of relevant agents for the management of obesity is strongly discouraged. Existing stock must be conserved for use in patients with diabetes. These shortages have serious clinical implications in the management of patients with type 2 diabetes.
 
For additional information and guidance, please find the link to the announcement here: CAS-ViewAlert (mhra.gov.uk)